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Computed tomographic coronary angiography (CTCA) is a non-invasive imaging modality which 
allows plaque burden and composition assessment and detection of plaque characteristics associated 
with increased vulnerability. In addition, CTCA-based coronary artery reconstruction enables local 
haemodynamic forces assessment, which regulate plaque formation and vascular inflammation and 
prediction of lesions that are prone to progress and cause events. However, the use of CTCA for 
vulnerable plaque detection in the clinical arena remains limited. To unlock the full potential of CTCA 
and enable its broad use, further work is needed to develop user-friendly processing tools that will allow 
fast and accurate analysis of CTCA, computational fluid dynamic modelling and evaluation of the local 
hemodynamic forces. The present study aims to develop a seamless platform that will overcome the 
limitations of CTCA and enable fast and accurate evaluation of plaque morphology and physiology. 
We will analyse imaging data from 70 patients with coronary artery disease who will undergo state-of-
the-art CTCA and near infrared spectroscopy-intravascular ultrasound imaging and develop and train 
algorithms that will take advantage of the intravascular imaging data to optimise vessel segmentation 
and plaque characterization. Furthermore, we will design an advanced module that will enable 
reconstruction of coronary artery anatomy from CTCA, blood flow simulation, shear stress estimation 
and comprehensive visualization of vessel pathophysiology. These advances are expected to facilitate 
the broad use of CTCA, not only for risk stratification but also for the evaluation of the effect of 
















There is growing evidence that vessel physiology and plaque characteristics are able to detect high-risk 
plaques that are likely to progress and cause cardiovascular events.(1-3) Accurate in vivo assessment 
of plaque characteristics is traditionally performed by intravascular imaging. Today, three intravascular 
imaging modalities are available in the clinical arena [intravascular ultrasound (IVUS), optical 
coherence tomography (OCT), and near infrared spectroscopy (NIRS)-IVUS]. These have been studied 
in large prospective studies and showed that they can provide useful prognostic information and detect 
vulnerable lesions and high-risk patients that are likely to suffer a cardiovascular event.(1, 2, 4) 
Histology studies have shown that NIRS-IVUS has an excellent accuracy in assessing plaque phenotype 
and it is the best modality for characterising its composition as it combines an ultrasound probe that 
gives information about plaque and calcific tissue burden and a NIRS probe that can accurately detect 
the lipid component.(5, 6) In addition the recently published Lipid Rich Plaque study has provide robust 
evidence that this modality enables detection of vulnerable plaques and patients and today NIRS-IVUS 
is the only FDA-approved imaging technique for the detection of plaques and patients that are at risk to 
suffer a cardiovascular event (2). Despite the potential of this modality in detecting vulnerable plaques, 
its use in the clinical arena for this purposes is limited. This is an invasive technique which can be only 
be used in patients undergoing coronary angiography. Intravascular imaging is associated with a risk of 
complications and it does not allow complete assessment of the entire coronary tree.  
Non-invasive imaging and in particular, computed tomographic coronary angiography (CTCA) have 
appeared as a promising alternative for the study of atherosclerosis and seems to be able to overcome 
limitations of intravascular imaging. Cumulative evidence has shown that CTCA can detect lumen and 
vessel wall dimensions and quantify plaque burden and composition.(7-9) Moreover, recent reports 
have shown that computational fluid dynamic (CFD) analysis is feasible in CTCA-derived 
reconstructions and that the estimated local hemodynamic forces have a value in detecting segments 
that are likely to exhibit disease progression.(10, 11) In addition, large scale retrospective studies have 
shown that CTCA can identify vulnerable plaques and patients at risk of suffering cardiovascular 
events. Recently, the EMERALD study has demonstrated that plaque characteristics and the local 
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hemodynamic forces estimated by CTCA have incremental value in differentiating lesions that caused 
a myocardial infarction from those that remained quiescent.(12) Despite these promising findings, 
CTCA is not used in everyday clinical practice for vulnerable plaque detection and patient risk 
stratification. This should be partially attributed to the increased time required for CTCA analysis as 
well as to the limitations of CTCA to accurately detect lumen and vessel wall borders and quantify 
plaque burden and composition – especially in calcified plaques.  In the present study, we aim to 
develop and validate methodologies that will overcome the above limitations and enable the use of 




The “Evaluation of the efficacy of computed tomographic coronary angiography in assessing coronary 
artery morphology and physiology” is a prospective observational multi-imaging single centre study. 
The primary objective of the study is to examine whether CTCA allows accurate assessment of coronary 
artery plaque phenotype using invasive imaging as the gold standard. Secondary objectives of the study 
are: 1) to develop segmentation algorithms and plaque characterisation methodologies that will enable 
accurate assessment of plaque burden and composition, 2) examine the efficacy of CTCA in assessing 
the local haemodynamic forces and 3) develop a seamless platform that will enable CTCA 
segmentation, plaque characterisation, blood flow simulation and evaluation of the endothelial shear 
stress (ESS) in less than 1 ½ hour per patient. 
 
Patient population 
Seventy patients with typical angina symptoms who had elective coronary angiography showing at least 
one obstructive lesion and are referred to Barts Heart Centre for further evaluation with a fractional 
flow reserve (FFR) study or percutaneous coronary intervention (PCI) will be considered for 
participation. The inclusion and exclusion criteria of the study are shown in Table 1. Patients who fulfil 
these criteria will be contacted by the research team and a copy of the patient information sheet will be 
provided. Patients who are keen to participate will be booked to attend two visits to the Barts Heart 
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Centre for: 1) study consenting followed by CTCA and pre-assessment clinic visit and 2) a 3-vessel 
intravascular imaging study along with PCI as required. Following the procedure, patients will be 
transferred back to the day case ward for monitoring and they will be discharged later that day. 
  
Patient withdrawal 
Patients will be free to withdraw consent at their own request at any time without the need to provide 
reasons for their decision. Additionally, the principal investigator will be able to withdraw a patient 
from the study if there are concerns about patient safety and well-being. Withdrawals will be 
documented in the case report form and in the patients’ medical records. 
 
Patient pre-assessment  
On the day of the pre-assessment visit, patient’s fitness for invasive angiography will be assessed by 
trained nurses as per Barts Health NHS Trust protocols. Blood samples (20mls) will be obtained to 
check for full blood count, renal function and lipid profile. Patients cardiovascular risk factors, 
revascularisation history and current medications will be recorded.  
 
Computed tomography coronary angiography   
CTCA will be performed after consenting using a third generation dual-source scanner (Somatom 
Force, Siemens Healthineers, Forchheim, Germany). Before the CT scan all patients will receive 
sublingual nitroglycerin (0.4 mg/dose) and those with heart rate >70 beats per minute, will also receive 
intravenous metoprolol (maximum 40 mg), provided there are no contraindications. The CTCA scan 
parameters include prospective ECG-triggered sequential scan mode, gantry rotation time of 250ms, 
128x2x0.5mm collimation with z-flying focal spot for both detectors, minimum tube voltage of 100kV 
and tube current determined by the scanner. A bolus of iodinated contrast agent (Omnipaque 350) which 
varies between 65 or 78mls depending on the patient’s body habitus will be injected intravenously at 
an injection rate of 4-5ml/s followed by 32 mls saline chaser with the same injection rate. A test bolus 
technique will be used to synchronise the start of image acquisition. All CT images will be digitally 




A senior interventional trainee and a consultant cardiologist will perform the coronary angiography 
according to Barts Health Trust protocols. The access route, choice of guide catheters and coronary 
wires will be left to the operators’ discretion. Heparin (intracoronary or intravenous according to the 
operator’s discretion) will be administered to maintain an ACT>250 throughout the procedure. All 
patients will receive 400 micrograms of intracoronary nitrate prior to image acquisition, provided there 
are no contraindications. Images will be acquired after optimal intubation of the guiding catheter; an 
effort will be made to avoid panning during angiography and acquire for each studied vessel at least 
two angiographic views, that are at least 25o apart, with good contrast opacification and minimal vessel 
foreshortening and overlapping. Before FFR or PCI – depending on the clinical need - NIRS-IVUS 
imaging will be performed in all the 3-epicardial vessels and their major side branches with diameter 
≥2mm. NIRS-IVUS will be performed by the Makoto™ imaging system (Infraredx, Burlington, MA) 
The catheter will be advanced 5mm distally to the most distal side branch that is visible in both 
angiography and CTCA imaging and will be pulled-back by a motorised pullback device that will 
withdraw the catheter at 0.5mm/s; images will be acquired at 30 frames per second and digitally 
archived. Patients will then undergo pressure wire study or PCI as per clinical indication.  
 
Image segmentation 
Imaging data will be anonymised and analysed offline blinded to clinical details by an expert analyst 
using dedicated workstation. Anatomical landmarks (i.e., side branches) identified in the CTCA and 
NIRS-IVUS imaging data will be used to define segments of interest – i.e., segments that have been 
assessed by both imaging modalities and have a lumen diameter ≥2mm. CTCA analysis will be 
performed by an expert analysist using the QAngioCT 2.1 Research Edition software that enables 
automated extraction of the luminal centreline, semi-automated detection of the lumen and outer vessel 
wall borders and quantification of the plaque burden and composition. NIRS-IVUS analysis will be 
performed by an operator with expertise in intravascular image analysis blinded to the CTCA analysis 
using dedicated software (QIvus 3.1, Medis Medical Imaging Systems, Leiden, The Netherlands). The 
inter- and intra-observer reliability of the expert analyst who will perform the NIRS-IVUS and CTCA 
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segmentation will be measured in 20 coronary arteries and reported. Lumen and outer vessel wall border 
detection will be performed in end-diastolic IVUS images while the presence of lipid component will 
be derived by the NIRS data that are displayed in a colour coded map called chemogram (yellow 
indicates increased probability and red low probability of lipid tissue). A metric of the lipid burden is 
the lipid core burden index (LCBI) which is computed as the fraction of the yellow pixels that 
correspond to lipid component divided by 1000. In addition, for each 2mm segments, the block 
chemogram is generated that provides a summary of the chemogram for this segment. The NIRS and 
IVUS imaging data will be used to characterise plaque composition and its phenotype.  
 
Vessel reconstruction, blood flow simulation and local haemodynamic forces assessment  
CTCA coronary artery segmentation will be performed using a module that automatically places the 
CTCA borders onto the luminal centreline and creates three dimensional (3D) surfaces of the lumen 
and outer vessel wall which can be processed with CFD techniques.(11) The segment of interest – i.e., 
the segment that has been assessed by both CTCA and NIRS-IVUS imaging – and its side branches 
will be reconstructed using this approach and blood flow simulation will be performed. An established 
and well validated methodology that relies on the fusion of NIRS-IVUS and the angiographic data will 
be used to reconstruct the segment of interest and its side branches (diameter >1mm).(13) Blood flow 
will be estimated by measuring the number of the angiographic frames required for the contrast dye to 
travel from the start to the end of the reconstructed model, the volume of the coronary model and cine 
frame rate.(14) In the obtained geometries, blood flow simulation will be performed using the same 
blood flow and inflow and outflow boundary conditions for the NIRS-IVUS and CTC-based 
reconstructions and the ESS distribution will be estimated (Figure 1).  
 
Data post-processing 
We anticipate NIRS-IVUS imaging to be performed on average in 2.5 vessels per patient; from these 
40 will be randomly selected and used to train algorithms for CTCA segmentation and plaque 
characterisation (training dataset) while the remaining data will be used for validation purposes 
(validation dataset). In the training set, the segments of interest will be divided in 2mm segments and 
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corresponding 2mm segments will be identified in the CTCA and NIRS-IVUS models. In each segment 
the following metrics will be estimated in NIRS-IVUS: mean lumen area, vessel wall area, plaque area 
and burden, mean calcific area, the LCBI and the predominant ESS. In addition, each segment will be 
classified as lipid-rich or non-lipid rich according to the block chemogram.(15) Similarly, in the CTCA 
models the mean lumen area, outer vessel wall area, plaque area, plaque burden, calcific area and the 
mean predominant ESS will be estimated for every 2mm segment and compared with the estimations 
of NIRS-IVUS. Several approaches will be tested to optimise the segmentation of the lumen and vessel 
wall borders in CTCA including machine learning techniques and the best will be selected. The adaptive 
Hounsfield unit cut-offs that best identify lipid and calcific tissue will be defined and spread-out vessel 
plots portraying the distribution of the lipid tissue in the CTCA models will be created and compared 
with the output of NIRS. The block chemogram in NIRS-IVUS will be used to identify the 2mm CTCA-
derived lipid cut-off that enables accurate classification of the 2mm segments as lipid or non-lipid rich. 
The accuracy of these cut-offs will be tested in the validation dataset. In addition, in the validation 
dataset the NIRS-IVUS data will be used to identify coronary lesions – defined as segments with a 
plaque burden >40% in 3 consecutive frames.(16) For each lesion, its remodelling index, calcific and 
lipid component and plaque burden will be used to characterise their phenotype and classify them as: 
pathological intimal thickening/fibrotic plaques, fibro-calcific plaques, fibroatheromas, and calcified 
fibroatheromas (6, 17, 18). The NIRS-IVUS lesion classification will be used as reference standard in 
order to assess the accuracy of CTCA in characterising lesion phenotype. 
 
Power calculation and statistical analyses 
The primary endpoint of the study is the ability of CTCA in detecting fibroatheromas. In the study of 
Garcia-Garcia et al that included 129 patients who underwent single vessel IVUS imaging,(16) 1.7 
lesions were identified per patient. In the study of Puri et al. 45% of the detected lesions were classified 
as fibroatheromas based on histology.(6) In this study, a maximum 4mm LCBI >178, a remodelling 
index >1.1 and a plaque burden >67% enabled detection of fibroatheromas with an excellent accuracy 
(c-index: 0.80). We anticipate that we will be able to perform NIRS-IVUS imaging in 2.5 coronary 
arteries per patient(19) and that CTCA imaging quality will be optimal in 93% of the studied 
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patients.(20, 21) Therefore, a sample size of 70 patients will allow us to study 162 vessels, of which 
120 vessels will be used for validation (203 lesions, of which 92 are fibroatheromas) purposes. This 
dataset is anticipated to provide 80% power to demonstrate that CTCA has a similar sensitivity to NIRS-
IVUS to detect fibroatheromas using the 5% significant level (AUC of CTCA 0.71-0.89 and assuming 
that the true sensitivity of NIRS-IVUS is 0.80).  
Secondary endpoints of the study are the accuracy of CTCA to identify: a) lipid-rich segments (using 
the block chemogram of NIRS-IVUS as the gold standard), and b) segments exposed to low ESS (<1Pa, 
using the ESS estimated in the NIRS-IVUS based reconstructions as the reference standard). 
Correlation and linear regression analysis will be used to investigate the associations between mean 
lumen, outer vessel wall, plaque area, mean plaque burden and calcific tissue area estimated in the 2mm 
segments in the NIRS-IVUS and CTCA models and mixed models with random intercept and slope 
will be used to correct for patient effects.  
 
Discussion  
Cumulative evidence has demonstrated that plaque composition determines its vulnerability and enables 
more accurate risk stratification. Intravascular imaging studies have shown that even single vessel-
plaque assessment provides useful prognostic information and identification of patients at risk.(2, 4, 22, 
23) Despite the increased cost and the risk of complications associated with intravascular imaging, this 
strategy may have a value in selected populations with a high cardiovascular risk such as the patients 
admitted with an acute coronary syndrome where the event rate at 1 year is as high as 20%. (24, 25) 
Modern submillimetre high resolution CTCA imaging allows non-invasive, complete assessment of the 
coronary tree and atherosclerotic plaques and offers a unique alternative in the study of atherosclerosis. 
Cumulative evidence has highlighted its value in assessing atheroma characteristics and identifying 
patients at risk for future events amongst individuals with no previous cardiac history, however its role 
in secondary prevention is yet to be explored at scale.(20, 26) This at least partially is attributed to the 
limited efficacy of the first generation CTCA scanners to assess complex atherosclerotic plaques and 
especially, lesions with an increased calcific component as well as the increased time required to process 
the CTCA imaging data.(8, 27, 28) 
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The objective of this study is to take advantage of the advances in CTCA imaging and use hybrid 
intravascular imaging to overcome well-known limitations of CTCA by developing a novel platform 
that will incorporate efficient methodologies for automated and reliable processing of the CTCA 
imaging data, coronary reconstruction and blood flow simulation in less than 1 ½ hour. To our 
knowledge this is the first prospective appropriately powered clinical study with a strict CTCA and 3-
vessel intravascular imaging protocol that aims to examine the efficacy of a 3rd generation CT in 
assessing plaque characteristics in patients with advanced coronary artery disease. Moreover, in contrast 
to other studies, we aim not only to validate but also train segmentation and plaque characterisation 
algorithms, recognise and minimise the effect of common artefacts (i.e., calcium blooming artefact) on 
CTCA analysis, and thus assess more accurately plaque characteristics in patients with 
extensive/complex coronary artery disease. These advances will allow us to conduct studies that will 
examine the value of CTCA imaging in stratifying cardiovascular risk in patients with established 
coronary artery disease. This objective is timely as several new therapies that target vulnerable patients 
have been recently introduced in the clinical arena (i.e., Evolocumab, Alirocumab, prolonged dual 
antiplatelet treatment with low dose Ticagrelor),(29-31) others have been tested in large clinical studies 
and are likely to have applications in due course (i.e., Canakinumab)(32) and others are currently 
undergoing clinical evaluation in large randomised control trials [i.e., Colchicine (NCT02551094), 
Incliseran (NCT03705234)]. The above medications, however have significant side effects or are 
associated with an increased cost and thus they should be used only in well-defined high-risk patients. 
Unlocking the full potential of CTCA imaging in assessing atheroma characteristics and estimating the 
local hemodynamic forces – which in intravascular imaging studies appear to enable more accurate 
detection of vulnerable plaques and high-risk patients(3, 33) – is essential for the broad use of this 
modality in the clinical arena. This will allow identification of patients that are likely to sustain a 
cardiovascular event and benefit from an aggressive treatment of atherosclerosis.(34)  
In addition, the platform that we envision to develop is expected to enhance the research applications 
of CTCA and facilitate the conduction of large clinical studies that will focus on the evaluation of the 
effects of new treatments on plaque growth. Moreover, this platform will enable assessment, in large 
asymptomatic population, the effects of local hemodynamic forces on the formation and destabilization 
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of vulnerable plaques. This would allow us to understand the interplay between plaque morphology and 
flow patterns and their long term effects on plaque evolution.  
 
Limitations 
One of the limitations of the present study is the inclusion of patients with stable angina. Therefore, in 
contrast to other reports it will not be able to evaluate the efficacy of CTCA in detecting culprit lesions 
that have caused an acute coronary event.(35, 36) In addition, we have excluded patients with severe 
chronic kidney disease, extensive coronary artery disease requiring surgical revascularisation and those 
who had previous coronary artery bypass grafting. These patients have advanced coronary artery 
disease with increased calcific burden. We acknowledge that, in these settings CTCA may be less 
accurate due to the blooming artefacts in assessing the lumen and outer vessel wall dimension and as 
well as quantification of the plaque burden.  
 
Ethical considerations 
The study protocol has been approved by the local and independent Research Ethics Committee (REC 
reference: 17/SC/0566) and will be conducted in agreement with the Declaration of Helsinki.  All the 
adverse events (AE) that are likely to occur during the study will be assessed for severity, causality, 
seriousness and expectedness as per the sponsor’s protocol; AE and serious adverse events (SAE) will 
be reported to the sponsor within five working days. If there is an increased event rate or concerns about 
patient safety during the conduction of the study, study termination will be considered.  
 
Dissemination 
We aim to complete recruitment by late-2019 and publications will be prepared in the mid of 2020. 
Dissemination of the results will focus on publications in peer-reviewed journals in cardiovascular 
medicine and selected engineering journals as well as presentations at national and international 
meetings. The study has been also registered in a public registry (http://clinicaltrials.gov 





The sponsor of the study is University College London; the study is jointly funded by British Heart 
Foundation (PG/17/18/32883), University College London Biomedical Resource Centre (BRC492B) 
and Rosetrees Trust (A1773).  
 
Summary 
Despite the wealth of data supporting the use for CTCA for the assessment of coronary luminal stenosis, 
the application of this modality for plaque characterisation and risk stratification remains limited. In 
this study, we aim to use intravascular imaging and in particular, NIRS-IVUS to train and validate 
segmentation and plaque characterisation methodologies and incorporate reconstruction and blood flow 
simulation algorithms in a fast and user-friendly software. This will enable the broad use of CTCA in 
the clinical arena for more accurate detection of high-risk patients and for the evaluation of the effects 
of emerging therapies on plaque progression.  
 
Disclosure Statement  
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Table 1. Study inclusion and exclusion criteria  
Inclusion criteria 
1. Patients with stable angina that have at least one obstructive lesion on elective diagnostic coronary 
angiography that require further assessment with intravascular imaging, invasive functional 
assessment or percutaneous coronary intervention 
2. Age 18-75 years old 
3. Patient is able and willing to provide their written consent 
Exclusion criteria  
1. History of previous coronary artery bypass graft surgery 
2. History of heart failure New York Heart Association (NYHA) IV or severe left ventricular systolic 
dysfunction <30% regardless of patient symptom status 
3. Documented allergy or inability to receive treatment with aspirin, heparin or thienopyridines 
4. Patients that require surgical revascularisation following diagnostic angiogram  
5. Renal impairment – estimated glomerular filtration rate of < 60 mL/min at screening.  
6. History of acute coronary syndrome in the last 3 months  
7. History of heart transplantation  
8. Life expectancy of less than one year  
9. Extensive coronary artery disease (i.e. multiple chronic total occlusions) or torturous coronary 

















Figure legends  
Figure 1. Example of the vessel segmentation, reconstruction and blood flow simulation for local 
haemodynamic forces assessment. (A). Coronary angiography of a right coronary artery (RCA). The 
segment of interest is defined by the most proximal and distal side branches seen on the NIRS-IVUS 
and CTCA. (B’). NIRS-IVUS cross-section showing an attenuated calcific plaque and (B’’) the 
corresponding chemogram indicating the lipid-rich plaque. (C). Coronary tree model of the same patient 
reconstructed using CTCA where the RCA has been highlighted. (D’) CTCA cross-section showing 
lumen (yellow) and vessel wall (orange) annotations and plaque characteristics as well as (D’’) the 
longitudinal view of the RCA segmentation. (E). 3D reconstruction model of the RCA derived from the 
CTCA analysis showing luminal (light blue), vessel (green) surface and overlying plaques. (F). The 
ESS is a colour-coded display of the 3D model (blue colour indicates low ESS and red as high ESS).  
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